Detalhe da pesquisa
1.
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Antimicrob Agents Chemother
; 68(5): e0154523, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557112
2.
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Clin Infect Dis
; 74(11): 1979-1985, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34467969
3.
In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis.
Antimicrob Agents Chemother
; 65(8): e0056221, 2021 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34001513
4.
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans.
Antimicrob Agents Chemother
; 65(3)2021 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33318003
5.
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates.
Antimicrob Agents Chemother
; 65(3)2021 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33317999
6.
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother
; 65(8): e0050821, 2021 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097491
7.
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1â3)-ß-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Antimicrob Agents Chemother
; 64(6)2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32179521
8.
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats.
Antimicrob Agents Chemother
; 63(2)2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478166
9.
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.
Antimicrob Agents Chemother
; 61(11)2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28827419
10.
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
Antimicrob Agents Chemother
; 61(8)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28533234
11.
SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.
Antimicrob Agents Chemother
; 61(3)2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28069658
12.
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.
Antimicrob Agents Chemother
; 61(9)2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28630180
13.
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
Antimicrob Agents Chemother
; 61(5)2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28223375
14.
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
Antimicrob Agents Chemother
; 61(4)2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28137806
15.
Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells.
Gastroenterology
; 147(2): 463-72, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24786893
16.
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
Hepatology
; 59(2): 434-42, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23939953
17.
Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
Hepatology
; 59(5): 1726-37, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24375637
18.
SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir.
Microbiol Spectr
; 12(2): e0298023, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197702
19.
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
J Hepatol
; 59(4): 684-95, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23742912
20.
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States.
J Hepatol
; 58(2): 212-6, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23022497